Leading the Way in Life Science Technologies

GEN Exclusives

More »

People in the News

More »
Feb 15, 2013 (Vol. 33, No. 4)

People in the News

  • Click Image To Enlarge +
    Alan Burns

    Alan Burns, vp of quality management at Sartorius Stedium Biotech, was elected to the board of directors of Rx-360. This is an international pharmaceutical supply chain consortium. Burns has been appointed for a three-year term, together with six other individuals.

  •  

    Supernus Pharmaceuticals added Victor Vaughn as svp of sales...C. Russell Allen is now president and CEO at Georgia Bio...Oxyrane hired James Weston as vp of regulatory affairs and Susan Flint as executive director and head of clinical operations...Fluidigm named Gerhard F. Burbach to its board of directors...Todd G. Johnson joined Pathway Genomics as vp of sales and marketing...ICON added Robert L. Howie Jr. as CMO.

     

  • Click Image To Enlarge +
    Julia A. Stephanus

    Aratana Therapeutics added Julia A. Stephanus as CCO. Prior to joining Aratana, Stephanus was director of the Companion Animal Global Franchise at Ceva Animal Health. She founded Summit VetPharm. Before that, Stephanus worked in sales and marketing positions for Pfizer.

  •  

    Ischemix hired David A. DeWahl Jr. as president and CEO...DiaMedica added Mark Robbins, Ph.D., as vp, clinical and regulatory affairs...Jonathan B. Lloyd Jones joined Columbia Laboratories as vp of finance and CFO...Divakar Ramakrishnan, Ph.D., is now svp of process development, manufacturing, and quality at Moderna...Aethlon Medical appointed Laszlo Radvanyi, Ph.D., to its scientific advisory board.

     

  • Click Image To Enlarge +
    Henrik Björkman, Ph.D.

    Henrik Björkman, Ph.D., is now chief technical officer and vp of technical affairs at Gyros. He joins Gyros from GE Healthcare Life Sciences, where he was most recently director, MicroCal R&D and senior integration manager. Formerly, Dr. Björkman was chief technology officer at Attana.

  •  

    Seegene hired John G. Hurrell, Ph.D., as senior evp...Verastem promoted Robert Forrester to president...Probiodrug elected Ronald Black, M.D., as CMO and Inge Lues, Ph.D., as chief development officer...EndoGastric Solutions added Pat Crilly, Ph.D., as vp, human asset development and Lilip Lau as svp, R&D...Teresa DeHaemer joined Clinical Site Services as senior enrollment specialist...Joseph M. Marasco, Ph.D., is now president of Diffinity Genomics.

     

  • Click Image To Enlarge +
    John C. Reed, M.D., Ph.D.

    Roche hired John C. Reed, M.D., Ph.D., as head of pharma research and early development and as a member of the corporate executive committee. Formerly, he was CEO at Sanford-Burnham Medical Research Institute. He also has served on the boards of directors at several companies.

  •  

    Global Virus Network appointed Kathleen Kennedy Townsend as chairperson and Lisa Paulsen, Romain Murenzi, G. Steven Burrill, Salim S. Abdool Karim, Andrew Cheng, Longde Wang, N. Scott Fine, Nicolas De Santis, and Raj Shah to its board of directors...Foundation Medicine hired Steven J. Kafka, Ph.D., as CBO...Bristol-Myers Squibb hired Mike Burgess, M.D., Ph.D., as svp, discovery medicine and clinical pharmacology...Novozymes hired Peder Holk Nielsen as president and CEO.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »